DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Kapidex (Dexlansoprazole) - Published Studies

 
 



Kapidex Related Published Studies

Well-designed clinical trials related to Kapidex (Dexlansoprazole)

Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease. [2013]

The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD. [2011.03]

The 12-month safety profile of dexlansoprazole, a proton pump inhibitor with a dual delayed release formulation, in patients with gastro-oesophageal reflux disease. [2011.02]

Lack of electrocardiographic effect of dexlansoprazole MR, a novel modified-release formulation of the proton pump inhibitor dexlansoprazole, in healthy participants. [2009.12]

Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience. [2009.11.15]

Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience. [2009.09.04]

Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel Dual Delayed Release formulation of a proton pump inhibitor--evidence for dosing flexibility. [2009.04.15]

Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis. [2009.04.01]

Effects of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor, on plasma gastrin levels in healthy subjects. [2009.04]

Drug Interaction Studies with Dexlansoprazole Modified Release (TAK-390MR), a Proton Pump Inhibitor with a Dual Delayed-Release Formulation : Results of Four Randomized, Double-Blind, Crossover, Placebo-Controlled, Single-Centre Studies. [2009]

Well-designed clinical trials possibly related to Kapidex (Dexlansoprazole)

Terlipressin for hepatorenal syndrome. [2012]

A multicenter, randomized, comparative study to determine the appropriate dose of lansoprazole for use in the diagnostic test for gastroesophageal reflux disease. [2011.09]

14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. [2011.08.06]

Second-line levofloxacin-based triple therapy's efficiency for Helicobacter pylori eradication in patients with peptic ulcer. [2011.08]

Preventive effects of lansoprazole and famotidine on gastric mucosal injury induced by low-dose aspirin in Helicobacter pylori-negative healthy volunteers. [2011.07]

Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term low-dose aspirin therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial. [2011.06]

Kefir improves the efficacy and tolerability of triple therapy in eradicating Helicobacter pylori. [2011.04]

BMI is superior to symptoms in predicting response to proton pump inhibitor: randomised trial in patients with upper gastrointestinal symptoms and normal endoscopy. [2011.04]

Comparison of two different treatment protocols in Helicobacter pylori eradication. [2011.02]

Proton pump inhibitor versus prokinetic therapy in patients with functional dyspepsia: is therapeutic response predicted by Rome III subgroups? [2011.02]

Relative bioavailability of prasugrel free base in comparison to prasugrel hydrochloride in the presence and in the absence of a proton pump inhibitor. [2011]

Triple therapy with ecabet sodium, amoxicillin and lansoprazole for 2 weeks as the rescue regimen for H. pylori infection. [2011]

Proton pump inhibitor dose-related healing rate of artificial ulcers after endoscopic submucosal dissection: a prospective randomized controlled trial. [2011]

Proton pump inhibitor therapy improves symptoms in postnasal drainage. [2010.12]

Management of recurrence of symptoms of gastroesophageal reflux disease: synergistic effect of rebamipide with 15 mg lansoprazole. [2010.12]

Comparative study of therapeutic effects of PPI and H2RA on ulcers during continuous aspirin therapy. [2010.11.14]

The gain in quality-adjusted life months by switching to esomeprazole in those with continued reflux symptoms in primary care: EncomPASS--a cluster-randomized trial. [2010.11]

Dilated intercellular space in chronic laryngitis and gastro-oesophageal reflux disease: at baseline and post-lansoprazole therapy. [2010.10]

Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial. [2010.08]

Clinical trial: chest pain caused by presumed gastro-oesophageal reflux in coronary artery disease - controlled study of lansoprazole vs. placebo. [2010.07]

Changes of gastric histology in patients with erosive oesophagitis receiving long-term lansoprazole maintenance therapy. [2010.07]

Basal protrusion of ulcers induced by endoscopic submucosal dissection (ESD) during treatment with proton pump inhibitors, and the suppressive effects of polaprezinc. [2010.05]

Long-term quality of life improvement in subjects with healed erosive esophagitis: treatment with lansoprazole. [2010.05]

Rebamipide may be comparable to H2 receptor antagonist in healing iatrogenic gastric ulcers created by endoscopic mucosal resection: a prospective randomized pilot study. [2010.04]

Effectiveness and safety of proton pump inhibitors in infantile gastroesophageal reflux disease. [2010.03]

[Levofloxacin-based triple therapy for first-line Helicobacter pylori eradication treatment: a multi-central, randomized, controlled clinical study] [2010.01.12]

Patient self-treatment using lansoprazole for frequent nighttime heartburn. Commentary. [2010.01]

Does pretreatment with lansoprazole influence Helicobacter pylori eradication rate and quality of life? [2010]

Clinical trial: chest pain caused by presumed gastro-oesophageal reflux in coronary artery disease - controlled study of lansoprazole vs. placebo. [2010]

Omeprazole-Mg 20.6 mg is superior to lansoprazole 15 mg for control of gastric acid: a comparison of over-the-counter doses of proton pump inhibitors. [2010]

Effectiveness and safety of proton pump inhibitors in infantile gastroesophageal reflux disease. [2010]

Impact of oesophagitis classification in evaluating healing of erosive oesophagitis after therapy with proton pump inhibitors: a pooled analysis. [2010]

Systematic review: standard- and double-dose proton pump inhibitors for the healing of severe erosive oesophagitis -- a mixed treatment comparison of randomized controlled trials. [2009.09.15]

Oxidative stress in Helicobacter pylori infection: does supplementation with vitamins C and E increase the eradication rate? [2009.08]

A randomized, single-blind study of lansoprazole for the prevention of exacerbations of chronic obstructive pulmonary disease in older patients. [2009.08]

Long-term efficacy of lansoprazole in preventing relapse of erosive reflux esophagitis. [2009.08]

High efficacy of bismuth subcitrate for Helicobacter pylori eradication in pangastritis. [2009.08]

Lansoprazole 15 mg once daily for 14 days is effective for treatment of frequent heartburn: results of 2 randomized, placebo-controlled, double-blind studies. [2009.07]

Triple or quadruple tetracycline-based therapies versus standard triple treatment for Helicobacter pylori treatment. [2009.07]

The clinical safety of long-term lansoprazole for the maintenance of healed erosive oesophagitis. [2009.06.15]

Lansoprazole for long-term maintenance therapy of erosive esophagitis: double-blind comparison with ranitidine. [2009.05]

Does long term therapy with lansoprazole slow progression of oesophageal involvement in systemic sclerosis? [2009.05]

Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. [2009.04]

Control of 24-hour intragastric acidity with morning dosing of immediate-release and delayed-release proton pump inhibitors in patients with GERD. [2009.04]

Controlled, household-randomized, open-label trial of the effect of treatment of Helicobacter pylori infection on iron deficiency among children in rural Alaska: results at 40 months. [2009.03.01]

Early effects of intravenous administrations of lansoprazole and famotidine on intragastric pH. [2009.03]

Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis. [2009.02.28]

Helicobacter pylori eradication in long-term proton pump inhibitor users is highly cost-effective: economic analysis of the HELPUP trial. [2008.12.01]

Helicobacter pylori eradication therapy may facilitate gastric ulcer healing after endoscopic mucosal resection: a prospective randomized study. [2008.12]

Evaluation of two triple-therapy regimens with metronidazole or clarithromycin for the eradication of H. pylori infection in Vietnamese children: a randomized, double-blind clinical trial. [2008.12]

Lafutidine versus lansoprazole in combination with clarithromycin and amoxicillin for one versus two weeks for Helicobacter pylori eradication in Korea. [2008.12]

Lansoprazole in globus pharyngeus: double-blind, randomized, placebo-controlled trial. [2008.10]

Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. [2008.08.02]

Comparison of the enteral and intravenous lansoprazole pharmacodynamic responses in critically ill patients. [2008.08.01]

Ninety-six-hour wireless oesophageal pH monitoring following proton pump inhibitor administration in NERD patients. [2008.07]

Treatment of Helicobacter pylori in surgical practice: A randomised trial of triple versus quadruple therapy in a rural district general hospital. [2008.06.28]

Intragastric pH with oral vs intravenous bolus plus infusion proton-pump inhibitor therapy in patients with bleeding ulcers. [2008.06]

Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians. [2008.05]

Estimation of the area under the concentration-time curve of racemic lansoprazole by using limited plasma concentration of lansoprazole enantiomers. [2008.05]

Stronger inhibition of gastric acid secretion by lafutidine, a novel H(2) receptor antagonist, than by the proton pump inhibitor lansoprazole. [2008.04.21]

Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. [2008.04]

Intravenous esomeprazole 40 mg vs. intravenous lansoprazole 30 mg for controlling intragastric acidity in healthy adults. [2008.03.15]

Clinical response to 2 dosing regimens of lansoprazole in infants with gastroesophageal reflux. [2008.03]

Greater Immediate Gastric Acid Suppression with Lansoprazole 30 mg Administered as a 2-Minute Intravenous Bolus Injection versus a 30-Minute Infusion. [2008.03]

Evaluation of three different proton pump inhibitors with amoxicillin and metronidazole in retreatment for Helicobacter pylori infection. [2008.02]

Comparison of three different second-line quadruple therapies including bismuth subcitrate in Turkish patients with non-ulcer dyspepsia who failed to eradicate Helicobacter pylori with a 14-day standard first-line therapy. [2008.01]

Age-dependent pharmacokinetics of lansoprazole in neonates and infants. [2008]

Safety and pharmacodynamics of lansoprazole in patients with gastroesophageal reflux disease aged <1 year. [2008]

Use of acid-suppressing drugs and the risk of bacterial gastroenteritis. [2007.12]

The efficacy of bismuth containing quadruple therapy as a first-line treatment option for Helicobacter pylori. [2007.11]

Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial. [2007.10]

Failures in a proton pump inhibitor therapeutic substitution program: lessons learned. [2007.10]

Comparison of four proton pump inhibitors for the short-term treatment of esophagitis in elderly patients. [2007.09.07]

Rebamipide, a gastro-protective and anti-inflammatory drug, promotes gastric ulcer healing following eradication therapy for Helicobacter pylori in a Japanese population: a randomized, double-blind, placebo-controlled trial. [2007.08]

Levofloxacin-Containing Triple Therapy to Eradicate the Persistent H. pylori after a Failed Conventional Triple Therapy. [2007.08]

Efficacy and Safety of Saccharomyces boulardii in the 14-day Triple Anti-Helicobacter pylori Therapy: A Prospective Randomized Placebo-Controlled Double-Blind Study. [2007.08]

Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for Helicobacter pylori infection after the standard triple therapy. [2007.08]

Improvement in symptoms after H(2)-receptor antagonist-based therapy for eradication of H pylori infection. [2007.07.28]

Initial treatment with lansoprazole in young dyspeptic patients with negative urea breath test result: a randomized controlled trial with 12-month follow-up. [2007.07]

Effects of uptake and efflux transporter inhibition on erythromycin breath test results. [2007.06]

Influence of rabeprazole and lansoprazole on the pharmacokinetics of tacrolimus in relation to CYP2C19, CYP3A5 and MDR1 polymorphisms in renal transplant recipients. [2007.05]

Proton pump inhibitors: effective first-line treatment for management of dyspepsia. [2007.04]

Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. [2007.04]

Efficacy of low-dose proton pump inhibitor (PPI) in the eradication of Helicobacter pylori following combination PPI/AC therapy in Japan. [2007.03]

Effect of Helicobacter pylori infection and acid blockade by lansoprazole on clarithromycin bioavailability. [2007.03]

Acid control with esomeprazole and lansoprazole: a comparative dose-response study. [2007.02]

Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms. [2007.01.15]

Effects of anti-Helicobacter pylori treatment and probiotic supplementation on intestinal microbiota. [2007.01]

High eradication rate of H. pylori with moxifloxacin-based treatment: a randomized controlled trial. [2007]

Eradication of Helicobacter pylori in Hemodialysis Patients. [2007]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017